Compare Becton Dickinson and Co (BDX) vs Blackrock Inc (BLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Blackrock Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Blackrock Inc trades at $1,148.83 (market cap $175.22B). The key difference: Blackrock Inc is far larger — about 3.6× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.34%). Which is the better fit depends on your goals.
| BDX | BLK | |
|---|---|---|
Market Cap | $48.93B | $175.22B |
Sector | Health | Financials |
52-Week High | $185.39 | $1.20K |
52-Week Low | $138.62 | $922.90 |
Enterprise Value | $65.03B | $176.32B |
Dividend Yield | 2.34% | 2.03% |
Volume | — | 641,547 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
BlackRock (BLK) trades at $1,136.39, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with revenue growth from $20.4B in 2024 to $24.2B in 2025, though net income margin compressed to 22.93%. Recent earnings beats and a 78.79% analyst buy rating support positive sentiment, while the stock trades near resistance at $1,144.
BLK presents a compelling investment case with consistent earnings outperformance and strong institutional support, though investors face risks from margin compression and legal scrutiny. The consensus price target of $1,350 suggests 18.8% upside potential, balanced by overbought technical indicators and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Blackrock Inc
BlackRock, Inc. provides investment management services to institutional clients and to retail investors through various investment vehicles. The Company manages funds, as well as offers risk management services. BlackRock serves governments, companies, and foundations worldwide.
Read more on BLK →
